The future of biomedical research? Illumina’s spatial transcriptomics could unlock unprecedented discoveries
Illumina, Inc. has introduced an innovative spatial transcriptomics technology, designed to significantly enhance the mapping of complex tissues and cellular interactions. The new technology, compatible ... Read More
The rising impact of Melanoma: Understanding the risks, causes, and advances in treatment
Melanoma, a severe form of skin cancer, originates in melanocytes, the pigment-producing cells responsible for skin color. Known for its aggressive nature, melanoma can metastasise ... Read More
Aptevo Therapeutics achieves major breakthrough with mipletamig in acute myeloid leukemia
Aptevo Therapeutics has unveiled remarkable findings from Cohort 1 of its RAINIER clinical trial for mipletamig, a bispecific antibody aimed at tackling acute myeloid leukemia ... Read More
Oxford Nanopore and UK Biobank to pioneer future of personalised medicine
In a major breakthrough for biomedical research, Oxford Nanopore Technologies and UK Biobank have announced a landmark collaboration to create the world’s first large-scale epigenetic ... Read More
OncoVerity accelerates AML treatment with Series A extension
OncoVerity, a leader in integrating bioinformatics with oncology drug development, has closed a Series A extension financing round, bolstered by its key investors, argenx and ... Read More
Amplia Therapeutics secures FDA fast track status for narmafotinib in pancreatic cancer, stock surges
Amplia Therapeutics Limited (ASX: ATX) has announced that its Focal Adhesion Kinase (FAK) inhibitor, narmafotinib, has been granted Fast Track Designation by the United States ... Read More
Breakthrough in breast cancer treatment? BriaCell Therapeutics shares soar 150%!
BriaCell Therapeutics Corp., a clinical-stage biotechnology company, saw its shares surge by more than 150% to $1.55 following the release of positive overall survival data ... Read More
Roche reports setback in lung cancer study with tiragolumab and tecentriq combination
Roche (SIX: RO, ROG; OTCQX: RHHBY) has announced disappointing results from the phase II/III SKYSCRAPER-06 study, aimed at evaluating the efficacy of tiragolumab plus Tecentriq ... Read More
Hinova Pharmaceuticals’ HP518 gets FDA fast track designation in triple-negative breast cancer
Hinova Pharmaceuticals Inc. (688302.SH), a trailblazer in the biopharmaceutical industry, has achieved a significant milestone with the U.S. Food and Drug Administration (FDA) granting Fast ... Read More
Antengene’s XPOVIO approved in China for diffuse large B-cell lymphoma
Antengene Corporation Limited, a commercial-stage global biopharmaceutical company, has announced a significant milestone with the China National Medical Products Administration (NMPA) approving a new indication ... Read More